Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

2078 - Molecular alterations and matched treatment in older patients: results from the MOSCATO 01 trial.

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Perrine Vuagnat

Citation

Annals of Oncology (2018) 29 (suppl_8): viii649-viii669. 10.1093/annonc/mdy303

Authors

P. Vuagnat1, C. Baldini1, L. Verlingue1, P. Martin Romano1, A. Varga1, A. Hollebecque1, S. Postel-Vinay1, A. Gazzah1, R. Bahleda1, A. Marabelle1, V. Ribrag1, S. Champiat2, J. Michot1, J. Soria3, C. Massard1

Author affiliations

  • 1 Drug Development Department (ditep), Gustave Roussy, 94800 - VILLEJUIF/FR
  • 2 Drug Development Department (ditep), Gustave Roussy, 94805 - Villejuif/FR
  • 3 Drug Development Department (ditep), Medimmune, 20878 - Gaithersburg/US
More

Resources

Abstract 2078

Background

Previous works in molecular portraits of cancer have shown differences by ages with the accumulation of somatic mutations, suggesting that older patients may have aged specific genomic profiles. However, there is a lack of data concerning genomic alterations in metastatic older patients. We aimed at analyzing the clinical and pathological characteristics and outcomes by genomic alterations of older patients enrolled in MOSCATO-01 trial.

Methods

We retrospectively collected data from MOSCATO-01 trial from all patients over > 70 years old enrolled from November 2011 to March 2016 and performed a descriptive analysis of this sub group of patients with advanced solid tumor.

Results

Among the 1035 patients enrolled in the MOSCATO trial, 85 patients (8,2%) over 70 years old were included, with a median age of 74 (range 71-86). Urologic cancers were the most frequent cancer. All tumor biopsies were performed and a molecular portrait was obtained in 66 patients (77.6%). Almost 40 different molecular alterations were identified. An actionable molecular alteration was identified in 46 patients (54%). Among them, 13 patients had ≥ 2 (range 1-5) actionable targets. The most frequent alteration pathways were: Pi3K (21%), NOTCH (11,3%), FGF and FGFR mutation (both 9.7%), PTEN (6,5%), FBXW7, MDM2 and EGFR (4,8% each). A total of 23 (27%) patients were treated with a targeted therapy matched to a genomic alteration, and 15 of them were enrolled in phase 1 or 2. The PFS2/PFS1 ratio was >1.3 in 31.8 % of the patients (7/22, one missing data). Among the 46 patients with actionable molecular alteration, median overall survival was better in the group of patient with matched therapy (18.4 vs 5.4 months, p = 0,07 NS).

Conclusions

The genomic profile > 70 years old is feasible in advanced geriatric malignancies and can lead to a better understanding in the biology of cancer among the elderly and could improve outcomes with molecular target agents.

Clinical trial identification

MOSCATO 01 (NCT01566019).

Legal entity responsible for the study

Christophe Massard.

Funding

Gustave Roussy.

Editorial Acknowledgement

Disclosure

L. Verlingue: Consultant: Adaptherapy. A. Hollebecque: Honoraria: Merck Serono; Consulting: Amgen; Expenses: Amgen, Servier. J-C. Soria: Employement and ownership: AstraZeneca; Honoraria and consulting: AstraZeneca, BMS, Pfizer, Roche, Sanofi, Pierre Fabre. C. Massard: Other relationship: Amgen, Astellas Pharma, AstraZeneca, Bayer, Celgene, Genentech, Ipsen, Novartis, Pfizer, Roche, Sanofi, Orion Corporation, Lilly Pharma, Janssen Inc. Pharmaceutical. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.